JMP reiterates Oscient at market outperform

Oscient Pharmaceuticals Corp. was reiterated at market outperform by JMP Securities analyst Adam Cutler as JMP continues to track Factive and Testim (Auxilium Pharmaceuticals) prescription volumes using NDC Health data. For the week ended May 19, Factive total prescriptions were 6,030 (5,843 new), or 0.95% of weekly prescriptions for the quinolone class of antibiotics, compared with 5,730 total prescriptions (5,587 new) in the previous week, or 0.91% of weekly prescriptions from the quinolone class. About 39,586 Factive prescriptions have been written in the second quarter, generating roughly $3.5 million in revenue. Total Testim scripts for the week ended May 19 were 5,523 compared with 5,826 for the previous week. Shares of the Waltham, Mass., biopharmaceutical company were down 3 cents, or 2.31%, at $1.27 on volume of 146,839 shares versus the three-month running average of 481,098 shares. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.